Reported 2026-05-23Lot GT10-052026-299.88% purity · 13.69 mg
Open COA
Lyophilized Peptides
Tirzepatide Research Reference — 10 mg
LY3298176
A synthetic, lipidated peptide research reference characterized in published studies as a dual agonist of human GLP-1R and GIPR.
CatalogGT-PW-10MG
ManufacturerRemetide
PurityTarget ≥99% by RP-HPLC; lot result controls
Pack10 mg
$93.00 Current catalog price; lot availability controls fulfillment.
AvailabilityIn stock
12604 in stock
For laboratory research use only. Not for human or veterinary use.
Tirzepatide Research Reference — 10 mg$93.00
01Lot documentationCOA and analytical-record model
02Defined specificationMethod and result remain lot specific
03Tracked fulfillmentShipping method and lot allocation confirmed at order review
04Responsible useNon-clinical laboratory context
Lot documentation
Current Certificate of Analysis
25 approved certificates are attached to this product record.
Reported 2026-05-23Lot GT10-052026-299.88% purity · 13.69 mg
Open COA
Reported 2026-05-08Lot GT10-052026-299.30% purity · 11.62 mg
Open COA
Reported 2026-05-08Lot GT10-052026-299.30% purity · 11.62 mg
Open COA
Reported 2026-05-08Lot GT10-052026-299.30% purity · 11.62 mg
Open COA
Reported 2026-03-11Lot GT10-032026-199.78% purity · 10.43 mg
Open COA
Reported 2026-03-11Lot GT110-032026-199.78% purity · 10.43 mg
Open COA
Reported 2025-12-18Lot GT10-8064199.856% purity · 9.91 mg
Open COA
Reported 2025-12-12Lot GT10-6041499.856% purity
Open COA
Reported 2025-12-12Lot GT10-6041499.856% purity · 10.29 mg
Open COA
Reported 2025-12-08Lot GT10-1069299.862% purity
Open COA
Reported 2025-12-08Lot GT10-1069299.862% purity · 10.16 mg
Open COA
Reported 2025-11-27Lot GT10-11202025-J99.906% purity
Open COA
Reported 2025-11-27Lot GI16-11202025-J99.906% purity · 11.09 mg
Open COA
Reported 2025-10-16Lot GT10-10142025-H99.98% purity · 12.24 mg
Open COA
Reported 2025-10-16Lot GT10-10142025-H99.98% purity · 12.24 mg
Open COA
Reported 2025-10-15Lot T1R1008192025-1099.957% purity · 12.72 mg
Open COA
Reported 2025-10-15Lot TIR1008192025-1099.957% purity · 12.72 mg
Open COA
Reported 2025-08-20Lot T1R 1008162025-1099.91% purity · 11.58 mg
Open COA
Reported 2025-08-20Lot TIR 1008162025-1099.91% purity · 11.58 mg
Open COA
Reported 2025-08-13Lot GT10-08112025-J99.76% purity
Open COA
Reported 2025-08-13Lot GT10-08112025-J99.76% purity · 9.77 mg
Open COA
Reported 2025-07-27Lot TIR 1007232025-0999.89% purity · 11.21 mg
Open COA
Reported 2025-07-27Lot TIR 1007232025-0999.89% purity · 11.21 mg
Open COA
Reported 2025-06-27Lot TIRZ1006202-N99.92% purity · 12.20 mg
Open COA
Technical information
Chemical & material record
Presented in a scientific-catalog format so the material can be evaluated by identity, form and documentation before purchase.
- Identity
- Tirzepatide research reference
- Synonyms
- LY3298176
- CAS number
- 2023788-19-2
- Molecular formula
- C225H348N48O68
- Formula weight
- 4,813.5 Da
- Sequence / identity note
- 39-residue modified peptide; sequence controlled in the technical record
- Manufacturer
- Remetide
- Manufacturing role
- Custom peptide synthesis and manufacture
- Form
- Lyophilized, non-sterile research material
- Purity specification
- Target ≥99% by RP-HPLC; lot result controls
- Storage
- -20°C, dry and protected from light; follow lot documentation
- Pack size
- 10 mg
- Catalog number
- GT-PW-10MG
Research context
Published research & product context
Published literature is presented separately from lot-specific identity, purity and analytical results.
Tirzepatide (LY3298176) is a 39-residue modified peptide studied as an agonist of glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR). Published work has characterized receptor signaling, receptor internalization and downstream metabolic endpoints in non-clinical models.
In human receptor-expressing HEK293 systems, reported cAMP EC50 values were 6.54 nM at GLP-1R and 1.01 nM at GIPR; receptor internalization was also evaluated at 100 nM. These literature values are assay specific and are not release criteria for the supplied material.
Selected published findings
- Induced cAMP signaling in HEK293 cells expressing human GLP-1R or GIPR.
- Induced internalization of GLP-1R and GIPR in receptor-expressing cellular systems.
- Was evaluated in mouse models for metabolic and airway-response endpoints.
References and product citations 3
- Willard, F.S., Douros, J.D., Gabe, M.B.N., et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 5(17), e140532 (2020).
- Samms, R.J., Coghlan, M.P., and Sloop, K.W. How may GIP enhance the therapeutic efficacy of GLP-1? Trends in Endocrinology & Metabolism 31(6), 410–421 (2020).
- Toki, S., Goleniewska, K., Zhang, J., et al. GIP receptor agonism suppresses allergic airway inflammation in obese mice. Journal of Allergy and Clinical Immunology (2023).
Literature interpretation: This summary describes published experimental literature and is not a lot specification, clinical claim, use instruction or representation that the supplied research material will reproduce a published result. This record intentionally excludes dosing, administration, clinical outcomes, patient eligibility and therapeutic comparisons.
Intended laboratory context
Illustrative applications
- Analytical method development
- Identity comparison
- Qualified receptor-assay research
- Controlled non-clinical laboratory investigation
Documentation package
Documentation
- PDFIllustrative Certificate of AnalysisSample
- PDFHPLC chromatogramSample
- PDFMass-spectrometry summarySample
- PDFMaterial handling statementSample
Not for clinical, diagnostic, compounding, therapeutic, human or veterinary use. Current labeling, specification and lot documentation control.
Need a current record?
Documentation before decision-making.
Reference GT-PW-10MG and the applicable lot when contacting technical support. Published files support evaluation but do not replace the approved lot COA or material specification.
View documentation model